Inventiva’s investigational oral therapy lanifibranor safely reduced blood sugar levels and eased signs of liver disease among people with metabolic dysfunction-associated steatohepatitis (MASH), a…
The Center for Disease Analysis (CDA) Foundation has granted $2.1 million in funding to 14 U.S. organizations to help diagnosed but untreated hepatitis…
A possible therapeutic target for fatty liver disease (FLD) has been identified by researchers studying the natural defense mechanisms of certain cave-dwelling fish. While…
The U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) for the treatment of people with noncirrhotic nonalcoholic steatohepatitis (NASH) — a severe type…
Up to six years of treatment with Livmarli (maralixibat), which is approved for reducing itch, or pruritus, in Alagille syndrome, prolonged survival and…
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…
Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…
Most liver transplant centers in the U.S. continue to use stigmatizing language on their websites that could make people with alcohol-associated liver disease (ALD)…
Pliant Therapeutics’ investigational oral treatment bexotegrast safely eases itching and is associated with signs of better liver function and less liver scarring, or fibrosis, in…
Bile acids, which aid the fat-digesting functions of bile fluid, remain elevated in the blood and urine of adult biliary atresia patients whose bile…
